228 related articles for article (PubMed ID: 28441372)
1. Assessing Response of High-Grade Gliomas to Immune Checkpoint Inhibitors.
Sahebjam S; Stallworth DG; Mokhtari S; Tran ND; Arrington JA
Cancer Control; 2017 Apr; 24(2):180-186. PubMed ID: 28441372
[TBL] [Abstract][Full Text] [Related]
2. Molecular imaging and advanced MRI findings following immunotherapy in patients with brain tumors.
Galldiks N; Lohmann P; Werner JM; Ceccon G; Fink GR; Langen KJ
Expert Rev Anticancer Ther; 2020 Jan; 20(1):9-15. PubMed ID: 31842635
[No Abstract] [Full Text] [Related]
3. Recent advances in the role of toll-like receptors and TLR agonists in immunotherapy for human glioma.
Deng S; Zhu S; Qiao Y; Liu YJ; Chen W; Zhao G; Chen J
Protein Cell; 2014 Dec; 5(12):899-911. PubMed ID: 25411122
[TBL] [Abstract][Full Text] [Related]
4. RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults.
Wen PY; van den Bent M; Youssef G; Cloughesy TF; Ellingson BM; Weller M; Galanis E; Barboriak DP; de Groot J; Gilbert MR; Huang R; Lassman AB; Mehta M; Molinaro AM; Preusser M; Rahman R; Shankar LK; Stupp R; Villanueva-Meyer JE; Wick W; Macdonald DR; Reardon DA; Vogelbaum MA; Chang SM
J Clin Oncol; 2023 Nov; 41(33):5187-5199. PubMed ID: 37774317
[TBL] [Abstract][Full Text] [Related]
5. MRI in Glioma Immunotherapy: Evidence, Pitfalls, and Perspectives.
Aquino D; Gioppo A; Finocchiaro G; Bruzzone MG; Cuccarini V
J Immunol Res; 2017; 2017():5813951. PubMed ID: 28512646
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy for glioma: Current management and future application.
Xu S; Tang L; Li X; Fan F; Liu Z
Cancer Lett; 2020 Apr; 476():1-12. PubMed ID: 32044356
[TBL] [Abstract][Full Text] [Related]
7. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.
Wen PY; Macdonald DR; Reardon DA; Cloughesy TF; Sorensen AG; Galanis E; Degroot J; Wick W; Gilbert MR; Lassman AB; Tsien C; Mikkelsen T; Wong ET; Chamberlain MC; Stupp R; Lamborn KR; Vogelbaum MA; van den Bent MJ; Chang SM
J Clin Oncol; 2010 Apr; 28(11):1963-72. PubMed ID: 20231676
[TBL] [Abstract][Full Text] [Related]
8. Concepts for Immunotherapies in Gliomas.
Platten M; Reardon DA
Semin Neurol; 2018 Feb; 38(1):62-72. PubMed ID: 29548053
[TBL] [Abstract][Full Text] [Related]
9. Comparison of linear and volumetric criteria in assessing tumor response in adult high-grade gliomas.
Shah GD; Kesari S; Xu R; Batchelor TT; O'Neill AM; Hochberg FH; Levy B; Bradshaw J; Wen PY
Neuro Oncol; 2006 Jan; 8(1):38-46. PubMed ID: 16443946
[TBL] [Abstract][Full Text] [Related]
10. Immunobiology and immunotherapeutic targeting of glioma stem cells.
Madany M; Thomas TM; Edwards L; Yu JS
Adv Exp Med Biol; 2015; 853():139-66. PubMed ID: 25895711
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy approaches in the treatment of malignant brain tumors.
Dunn-Pirio AM; Vlahovic G
Cancer; 2017 Mar; 123(5):734-750. PubMed ID: 27875627
[TBL] [Abstract][Full Text] [Related]
12. Novel therapies for malignant gliomas.
Cavaliere R; Wen PY; Schiff D
Neurol Clin; 2007 Nov; 25(4):1141-71, x. PubMed ID: 17964029
[TBL] [Abstract][Full Text] [Related]
13. PDIA5 is Correlated With Immune Infiltration and Predicts Poor Prognosis in Gliomas.
Zhang H; He J; Dai Z; Wang Z; Liang X; He F; Xia Z; Feng S; Cao H; Zhang L; Cheng Q
Front Immunol; 2021; 12():628966. PubMed ID: 33664747
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy for gliomas: shedding light on progress in preclinical and clinical development.
Garcia-Fabiani MB; Ventosa M; Comba A; Candolfi M; Nicola Candia AJ; Alghamri MS; Kadiyala P; Carney S; Faisal SM; Schwendeman A; Moon JJ; Scheetz L; Lahann J; Mauser A; Lowenstein PR; Castro MG
Expert Opin Investig Drugs; 2020 Jul; 29(7):659-684. PubMed ID: 32400216
[TBL] [Abstract][Full Text] [Related]
15. Assessment of Brain Tumor Response: RANO and Its Offspring.
Eisele SC; Wen PY; Lee EQ
Curr Treat Options Oncol; 2016 Jul; 17(7):35. PubMed ID: 27262709
[TBL] [Abstract][Full Text] [Related]
16. Longitudinal DSC-MRI for Distinguishing Tumor Recurrence From Pseudoprogression in Patients With a High-grade Glioma.
Boxerman JL; Ellingson BM; Jeyapalan S; Elinzano H; Harris RJ; Rogg JM; Pope WB; Safran H
Am J Clin Oncol; 2017 Jun; 40(3):228-234. PubMed ID: 25436828
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy in Gliomas.
Weant MP; Jesús CM; Yerram P
Semin Oncol Nurs; 2018 Dec; 34(5):501-512. PubMed ID: 30396808
[TBL] [Abstract][Full Text] [Related]
18. Current standards and new concepts in MRI and PET response assessment of antiangiogenic therapies in high-grade glioma patients.
Hutterer M; Hattingen E; Palm C; Proescholdt MA; Hau P
Neuro Oncol; 2015 Jun; 17(6):784-800. PubMed ID: 25543124
[TBL] [Abstract][Full Text] [Related]
19. Monitoring immune responses after glioma vaccine immunotherapy.
Jian B; Yang I; Parsa AT
Neurosurg Clin N Am; 2010 Jan; 21(1):195-9. PubMed ID: 19944978
[TBL] [Abstract][Full Text] [Related]
20. Genetics and immunotherapy: using the genetic landscape of gliomas to inform management strategies.
Wang JY; Bettegowda C
J Neurooncol; 2015 Jul; 123(3):373-83. PubMed ID: 25697584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
